- Home
- AMPX vs OCS Comparison
AMPX vs OCS Comparison
Compare AMPX & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPX
- OCS
- Stock Information
- Founded
- AMPX 2008
- OCS 2003
- Country
- AMPX United States
- OCS Switzerland
- Employees
- AMPX N/A
- OCS N/A
- Industry
- AMPX Industrial Machinery/Components
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- AMPX Miscellaneous
- OCS Health Care
- Exchange
- AMPX Nasdaq
- OCS Nasdaq
- Market Cap
- AMPX 952.3M
- OCS 956.4M
- IPO Year
- AMPX N/A
- OCS N/A
- Fundamental
- Price
- AMPX $10.39
- OCS $17.36
- Analyst Decision
- AMPX Strong Buy
- OCS Strong Buy
- Analyst Count
- AMPX 7
- OCS 4
- Target Price
- AMPX $12.67
- OCS $35.75
- AVG Volume (30 Days)
- AMPX 7.1M
- OCS 14.8K
- Earning Date
- AMPX 11-06-2025
- OCS 11-06-2025
- Dividend Yield
- AMPX N/A
- OCS N/A
- EPS Growth
- AMPX N/A
- OCS N/A
- EPS
- AMPX N/A
- OCS N/A
- Revenue
- AMPX $44,837,000.00
- OCS $960,668.00
- Revenue This Year
- AMPX $172.99
- OCS $11.49
- Revenue Next Year
- AMPX $171.90
- OCS $1,784.02
- P/E Ratio
- AMPX N/A
- OCS N/A
- Revenue Growth
- AMPX 260.92
- OCS N/A
- 52 Week Low
- AMPX $0.81
- OCS $11.78
- 52 Week High
- AMPX $10.41
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- AMPX 75.26
- OCS 49.17
- Support Level
- AMPX $8.08
- OCS $16.94
- Resistance Level
- AMPX $8.47
- OCS $17.75
- Average True Range (ATR)
- AMPX 0.72
- OCS 0.40
- MACD
- AMPX 0.26
- OCS 0.10
- Stochastic Oscillator
- AMPX 98.94
- OCS 77.71
About AMPX Amprius Technologies Inc.
Amprius Technologies Inc is engaged in the production of silicon anodes for high-energy-density lithium-ion batteries. The company develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (EV) and light electric vehicle (LEV) industries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.